Alicia K Morgans1, Kang-Hsien Fan2, Tatsuki Koyama2, Peter C Albertsen3, Michael Goodman4, Ann S Hamilton5, Richard M Hoffman6, Janet L Stanford7, Antoinette M Stroup8, Matthew J Resnick9, Daniel A Barocas9, David F Penson10. 1. School of Medicine, Vanderbilt University, Nashville, Tennessee. Electronic address: alicia.morgans@vanderbilt.edu. 2. School of Medicine, Vanderbilt University, Nashville, Tennessee; Center for Quantitative Sciences and Department of Biostatistics, Vanderbilt University, Nashville, Tennessee. 3. University of Connecticut Health Center, Farmington, Connecticut. 4. Emory University, Atlanta, Georgia. 5. Keck School of Medicine, University of Southern California, Los Angeles, California. 6. University of New Mexico, Albuquerque, New Mexico. 7. Fred Hutchinson Cancer Research Center, Seattle, Washington. 8. University of Utah, Salt Lake City, Utah. 9. School of Medicine, Vanderbilt University, Nashville, Tennessee. 10. School of Medicine, Vanderbilt University, Nashville, Tennessee; Geriatric Research, Education and Clinical Center, Tennessee Valley Veterans Administration Healthcare System, Nashville, Tennessee.
Abstract
PURPOSE: Observational data suggest that androgen deprivation therapy increases the risk of diabetes and cardiovascular disease. Using data from the population based PCOS we evaluated whether age at diagnosis and comorbidity impact the association of androgen deprivation therapy with incident diabetes and cardiovascular disease. MATERIALS AND METHODS: We identified men with nonmetastatic prostate cancer diagnosed from 1994 to 1995 who were followed through 2009 to 2010. We used multivariable logistic regression models to assess the relationship of androgen deprivation therapy exposure (2 or fewer years, greater than 2 years or none) with incident diabetes and cardiovascular disease, adjusting for age at diagnosis, race, stage and comorbidity. RESULTS: Of 3,526 eligible study participants 2,985 without diabetes and 3,112 without cardiovascular disease comprised the cohorts at risk. Androgen deprivation therapy was not associated with an increased risk of diabetes or cardiovascular disease in men diagnosed with prostate cancer before age 70 years. Prolonged androgen deprivation therapy and increasing age at diagnosis in older men was associated with an increased risk of diabetes (at age 76 years OR 2.1, 95% CI 1.0-4.4) and cardiovascular disease (at age 74 years OR 1.9, 95% CI 1.0-3.5). Men with comorbidities were at greater risk for diabetes (OR 4.3, 95% CI 2.3-7.9) and cardiovascular disease (OR 8.1, 95% CI 4.3-15.5) than men without comorbidities. CONCLUSIONS: Prolonged androgen deprivation therapy exposure increases the risk of cardiovascular disease and diabetes in men diagnosed with prostate cancer who are older than approximately 75 years, especially those with other comorbidities. Older men who receive prolonged androgen deprivation therapy should be closely monitored for diabetes and cardiovascular disease.
PURPOSE: Observational data suggest that androgen deprivation therapy increases the risk of diabetes and cardiovascular disease. Using data from the population based PCOS we evaluated whether age at diagnosis and comorbidity impact the association of androgen deprivation therapy with incident diabetes and cardiovascular disease. MATERIALS AND METHODS: We identified men with nonmetastatic prostate cancer diagnosed from 1994 to 1995 who were followed through 2009 to 2010. We used multivariable logistic regression models to assess the relationship of androgen deprivation therapy exposure (2 or fewer years, greater than 2 years or none) with incident diabetes and cardiovascular disease, adjusting for age at diagnosis, race, stage and comorbidity. RESULTS: Of 3,526 eligible study participants 2,985 without diabetes and 3,112 without cardiovascular disease comprised the cohorts at risk. Androgen deprivation therapy was not associated with an increased risk of diabetes or cardiovascular disease in men diagnosed with prostate cancer before age 70 years. Prolonged androgen deprivation therapy and increasing age at diagnosis in older men was associated with an increased risk of diabetes (at age 76 years OR 2.1, 95% CI 1.0-4.4) and cardiovascular disease (at age 74 years OR 1.9, 95% CI 1.0-3.5). Men with comorbidities were at greater risk for diabetes (OR 4.3, 95% CI 2.3-7.9) and cardiovascular disease (OR 8.1, 95% CI 4.3-15.5) than men without comorbidities. CONCLUSIONS: Prolonged androgen deprivation therapy exposure increases the risk of cardiovascular disease and diabetes in men diagnosed with prostate cancer who are older than approximately 75 years, especially those with other comorbidities. Older men who receive prolonged androgen deprivation therapy should be closely monitored for diabetes and cardiovascular disease.
Authors: Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: A L Potosky; L C Harlan; J L Stanford; F D Gilliland; A S Hamilton; P C Albertsen; J W Eley; J M Liff; D Deapen; R A Stephenson; J Legler; C E Ferrans; J A Talcott; M S Litwin Journal: J Natl Cancer Inst Date: 1999-10-20 Impact factor: 13.506
Authors: A L Potosky; J Legler; P C Albertsen; J L Stanford; F D Gilliland; A S Hamilton; J W Eley; R A Stephenson; L C Harlan Journal: J Natl Cancer Inst Date: 2000-10-04 Impact factor: 13.506
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Christopher S Saigal; John L Gore; Tracey L Krupski; Janet Hanley; Matthias Schonlau; Mark S Litwin Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Arnold L Potosky; William W Davis; Richard M Hoffman; Janet L Stanford; Robert A Stephenson; David F Penson; Linda C Harlan Journal: J Natl Cancer Inst Date: 2004-09-15 Impact factor: 13.506
Authors: Daniar K Osmonov; Alexey V Aksenov; David Trick; Carsten M Naumann; Moritz F Hamann; Amr Abou Faddan; Klaus-Peter Jünemann Journal: BMC Urol Date: 2016-09-06 Impact factor: 2.264
Authors: Joanna Sulicka; Agnieszka Pac; Monika Puzianowska-Kuźnicka; Tomasz Zdrojewski; Jerzy Chudek; Beata Tobiasz-Adamczyk; Małgorzata Mossakowska; Anna Skalska; Andrzej Więcek; Tomasz Grodzicki Journal: J Cancer Surviv Date: 2018-01-09 Impact factor: 4.442
Authors: Neal D Shore; Emmanuel S Antonarakis; Michael S Cookson; E David Crawford; Alicia K Morgans; David M Albala; Jason Hafron; Richard G Harris; Daniel Saltzstein; Gordon A Brown; Jonathan Henderson; Benjamin Lowentritt; Jeffrey M Spier; Raoul Concepcion Journal: Prostate Date: 2020-03-04 Impact factor: 4.104
Authors: Cindy K Blair; Elizabeth M Harding; Prajakta Adsul; Sara Moran; Dolores Guest; Kathy Clough; Andrew L Sussman; Dorothy Duff; Linda S Cook; Joseph Rodman; Zoneddy Dayao; Ursa Brown-Glaberman; Towela V King; V Shane Pankratz; Eduardo Servin; Sally Davis; Wendy Demark-Wahnefried Journal: Contemp Clin Trials Commun Date: 2021-02-11
Authors: Azariyas A Challa; Adam Christopher Calaway; Jennifer Cullen; Jorge Garcia; Nihar Desai; Neal L Weintraub; Anita Deswal; Shelby Kutty; Ajay Vallakati; Daniel Addison; Ragavendra Baliga; Courtney M Campbell; Avirup Guha Journal: Curr Treat Options Oncol Date: 2021-04-17